Christopher Evans, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Johnson & Johnson at 36.8% of the total. Reporting peaked in 2019 at $82,427 and has fallen 99.8% since, to $134 in 2025. Among urology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $1450.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$68K
- Astellas Pharma Inc$32K
- Astellas Pharma US Inc$28K
- Astellas Pharma Global Development$26K
- Myovant Sciences Inc.$13K
- Pfizer$12K
- plus $7K from 10 others
Across 289 payments — averaging $8979.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medivation LLC.$1.9M
- Janssen Research & Development, LLC$451K
- Pfizer$123K
- Astellas Pharma Global Development$81K
What the payments were for
- Consulting fees$61,80534%
- Speaking & faculty fees$84,47046%
- Travel & lodging$34,22119%
- Food & beverage$3,6402%
- Education$350%
- Gifts$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 56 | $67,747 |
| Astellas Pharma Inc | 22 | $31,704 |
| Astellas Pharma US Inc | 6 | $27,766 |
| Astellas Pharma Global Development | 5 | $25,522 |
| Myovant Sciences Inc. | 7 | $13,147 |
| Pfizer | 15 | $11,614 |
| Janssen Scientific Affairs, LLC | 4 | $4,449 |
| Progenics Pharmaceuticals, Inc. | 1 | $1,625 |
| Janssen Research & Development, LLC | 3 | $416 |
| Intuitive Surgical | 1 | $90 |
| Boston Scientific | 1 | $43 |
| AstraZeneca | 1 | $35 |
| Sobi, Inc | 1 | $34 |
| AbbVie | 1 | $29 |
| Biotissue Holdings Inc. | 2 | $23 |
| 180 Medical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$184,261 in reported general payments places this provider in the 95th percentile of 63 urology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 34 | $295 |
| Finasteride | 18 | $160 |
Paid to pharmacies, not to this prescriber.
Other urology in Reno
- Eric KimReno$24K
- Nicholas HauserReno$12K
- Angelo KanellosReno$11K
- Timothy SuttleReno$8K
- Ross AndersonReno$7K
- Matthew McCormackReno$3K
- Chloe ShenkReno$3K
- Christopher TamReno$3K
- Dielle DuvalReno$3K
- Remy LambertsReno$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.